Hypericin-photodynamic therapy inhibits proliferation and induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes cell line MH7A

Document Type: Original Article

Authors

1 Department of Orthopedics, No. 91 Central hospital of Liberation Army, Jiaozuo 454150, Henan province, China

2 Faculty of Graduate Studies, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China

3 Department of Orthopedics, Luoyang Orthopedic Hospital of Henan Province, Luoyang 471000, Henan Province, China

Abstract

Objective(s): To elucidate the effects and potential mechanisms of hypericin-photodynamic therapy (HYP-PDT) for treating the human rheumatoid arthritis (RA) fibroblast-like synoviocyte (FLS) MH7A cell-line.
Materials and Methods: MH7A cells were subjected to HYP-PDT intervention and apoptosis was evaluated via MTT, nuclear staining, and flowcytometry analyses. Intracellular reactive oxygen species (ROS) were measured with the fluorescent probe 2’7’-dichlorofluorescein diacetate (DCFH-DA). To verify the effects of HYP on apoptotic and nuclear factor kappa-B (NF-κB) pathways, caspase-8, 9, poly-ADP-ribose polymerase (PARP), phosphorylated (p)-NF-κB p65, NF-κB p65 and p-IκBα protein expressions were quantified with western blot. Quantitative real-time PCR was used to assay NF-κB p65 mRNA.
Results: HYP-PDT inhibited MH7A cell viability and induced apoptosis in a dose-dependent manner. Meanwhile, intracellular ROS levels increased significantly after HYP-PDT treatment. Furthermore, the expression of cleaved caspase-9 and PARP was increased by HYP-PDT treatment, with a concurrent decline in NF-κB.
Conclusion: HYP-PDT induces apoptosis in MH7A cells, at least partially, via generation of ROS, regulation of the apoptotic pathway and suppression of the NF-κB pathway. These findings suggest that HYP-PDT may be a potential treatment for RA.

Keywords

Main Subjects


1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423:356-361.

2. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009; 11:229.

3. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27:269-281.

4. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233:233-255.

5. Chen H, Pan J, Wang JD, Liao QM, Xia XR. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes. Inflammation 2016; 39:39-46.

6. Baier A, Meineckel I, Gay S, Pap T. Apoptosis in rheumatoid arthritis. Curr Opin Rheumatol 2003; 15:274-279.

7. Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology: Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000; 2:361-367.

8. Lefevre S, Meier FM, Neumann E, Muller-Ladner U. Role of synovial fibroblasts in rheumatoid arthritis. Curr Pharm Des 2015; 21:130-141.

9. Jankowska A, Wiecek P, Burczynska B. Effect of photodynamic therapy on proliferation and apoptosis of 3T3 fibroblasts and HeLa cells. Photomed Laser Surg 2008; 26:343-347.

10. Torikai E, Kageyama Y, Kohno E, Hirano T, Koide Y, Terakawa S, et al. Photodynamic therapy using talaporfin sodium for synovial membrane from rheumatoid arthritis patients and collagen-induced arthritis rats. Clin Rheumatol 2008; 27:751-761.

11. Zhao C, Ur Rehman F, Yang Y, Li X, Zhang D, Jiang H, et al. Bio-imaging and Photodynamic therapy with tetra sulphonatophenyl porphyrin (TSPP)-TiO2 nanowhiskers: new approaches in rheumatoid arthritis theranostics. Sci Rep 2015; 5:11518.

12. Byun JY, Choi HY, Myung KB, Choi YW. Expression of IL-10, TGF-beta(1) and TNF-alpha in cultured keratinocytes (HaCaT Cells) after IPL treatment or ALA-IPL photodynamic treatment. Ann Dermatol 2009; 21:12-17.

13. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011; 61:250-281.

14. Lin XX, Wang W, Wu SF, Yang C, Chang TS. Treatment of capillary vascular malformation (port-wine stains) with photochemotherapy. Plast Reconstr Surg 1997; 99:1826-1830.

15. Gu Y, Huang NY, Liang J, Pan YM, Liu FG. Clinical study of 1949 cases of port wine stains treated with vascular photodynamic therapy (Gu's PDT). Ann Dermatol Venereol 2007; 134:241-244.

16. Luksiene Z, de Witte PA. Hypericin as novel and promising photodynamic therapy tool: studies on intracellular accumulation capacity and growth inhibition efficiency. Medicina (Kaunas) 2003; 39:677-682.

17. Barathan M, Mariappan V, Shankar EM, Abdullah BJ, Goh KL, Vadivelu J. Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases. Cell Death Dis 2013; 4:e697.

18. Popovic A, Wiggins T, Davids LM. Differential susceptibility of primary cultured human skin cells to hypericin PDT in an in vitro model. J Photochem Photobiol B 2015; 149:249-256.

19. Kashef N, Karami S, Djavid GE. Phototoxic effect of hypericin alone and in combination with acetylcysteine on Staphylococcus aureus biofilms. Photodiagnosis Photodyn Ther 2015; 12:186-192.

20. Nakajima N, Kawashima N. A basic study on hypericin-PDT in vitro. Photodiagnosis Photodyn Ther 2012; 9:196-203.

21. Brockmoller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30 Suppl 2:94-101.

22. Lima AM, Pizzol CD, Monteiro FB, Creczynski-Pasa TB, Andrade GP, Ribeiro AO, et al. Hypericin encapsulated in solid lipid nanoparticles: phototoxicity and photodynamic efficiency. J Photochem Photobiol B 2013; 125:146-154.

23. Zhang J, Shao L, Wu C, Lu H, Xu R. Hypericin-mediated photodynamic therapy induces apoptosis of myoloma SP2/0 cells depended on caspase activity in vitro. Cancer Cell Int 2015; 15:58.

24. Xu Y, Wang D, Zhuang Z, Jin K, Zheng L, Yang Q, et al. Hypericin-mediated photodynamic therapy induces apoptosis in K562 human leukemia cells through JNK pathway modulation. Mol Med Rep 2015; 12:6475-6482.

25. Kleemann B, Loos B, Scriba TJ, Lang D, Davids LM. St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death. PLoS One 2014; 9:e103762.

26. Li ZH, Meng DS, Li YY, Lu LC, Yu CP, Zhang Q, et al. Hypericin damages the ectatic capillaries in a Roman cockscomb model and inhibits the growth of human endothelial cells more potently than hematoporphyrin does through induction of apoptosis. Photochem Photobiol 2014; 90:1368-1375.

27. Miyazawa K, Mori A, Okudaira H. Establishment and characterization of a novel human rheumatoid fibroblast-like synoviocyte line, MH7A, immortalized with SV40 T antigen. J Biochem 1998; 124:1153-1162.

28. Zhang Q, Li ZH, Li YY, Shi SJ, Zhou SW, Fu YY, et al. Hypericin-photodynamic therapy induces human umbilical vein endothelial cell apoptosis. Sci Rep 2015; 5:18398.

29. Kammerer R, Buchner A, Palluch P, Pongratz T, Oboukhovskij K, Beyer W, et al. Induction of immune mediators in glioma and prostate cancer cells by non-lethal photodynamic therapy. PLoS One 2011; 6:e21834.

30. Krammer B, Verwanger T. Molecular response to hypericin-induced photodamage. Curr Med Chem 2012; 19:793-798.

31. Zheng Y, Yin G, Le V, Zhang A, Chen S, Liang X, et al. Photodynamic-therapy activates immune response by disrupting immunity homeostasis of tumor cells, which generates vaccine for cancer therapy. Int J Biol Sci 2016; 12:120-132.

32. Mirmalek SA, Azizi MA, Jangholi E, Yadollah-Damavandi S, Javidi MA, Parsa Y, et al. Cytotoxic and apoptogenic effect of hypericin, the bioactive component of Hypericum perforatum on the MCF-7 human breast cancer cell line. Cancer Cell Int 2015; 16:3.

33. Gabriel D, Busso N, So A, van den Bergh H, Gurny R, Lange N. Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis. J Control Release 2009; 138:225-234.

34. Fang N, Li Q, Yu S, Zhang J, He L, Ronis MJ, et al. Inhibition of growth and induction of apoptosis in human cancer cell lines by an ethyl acetate fraction from shiitake mushrooms. J Altern Complement Med 2006; 12:125-132.

35. Sanovic R, Verwanger T, Hartl A, Krammer B. Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma. Photodiagnosis Photodyn Ther 2011; 8:291-296.

36. Stupakova V, Varinska L, Mirossay A, Sarissky M, Mojzis J, Dankovcik R, et al. Photodynamic effect of hypericin in primary cultures of human umbilical endothelial cells and glioma cell lines. Phytother Res 2009; 23:827-832.

37. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000; 5:415-418.

38. Zheng X, Wu J, Shao Q, Li X, Kou J, Zhu X, et al. Apoptosis of THP-1 macrophages induced by pseudohypericin-mediated sonodynamic therapy through the mitochondria-caspase pathway. Cell Physiol Biochem 2016; 38:545-557.

39. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312.

40. Bulina ME, Chudakov DM, Britanova OV, Yanushevich YG, Staroverov DB, Chepurnykh TV, et al. A genetically encoded photosensitizer. Nat Biotechnol 2006; 24:95-99.

41. Butler MC, Itotia PN, Sullivan JM. A high-throughput biophotonics instrument to screen for novel ocular photosensitizing therapeutic agents. Invest Ophthalmol Vis Sci 2010; 51:2705-2720.

42. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21:5673-5683.

43. Hwang JR, Jo K, Lee Y, Sung BJ, Park YW, Lee JH. Upregulation of CD9 in ovarian cancer is related to the induction of TNF-alpha gene expression and constitutive NF-kappaB activation. Carcinogenesis 2012; 33:77-83.

44. Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, et al. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer 2010; 9:97.

45. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.

46. Pereira SG, Oakley F. Nuclear factor-kappaB1: regulation and function. Int J Biochem Cell Biol 2008; 40:1425-1430.

47. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27:693-733.

48. Makarov SS. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 2001; 3:200-206.

49. Yin G, Wang Y, Cen XM, Yang M, Liang Y, Xie QB. Lipid peroxidation-mediated inflammation promotes cell apoptosis through activation of NF-kappaB pathway in rheumatoid arthritis synovial cells. Mediators Inflamm 2015; 2015:460310.

50. Aupperle KR, Bennett BL, Boyle DL, Tak PP, Manning AM, Firestein GS. NF-kappa B regulation by I kappa B kinase in primary fibroblast-like synoviocytes. J Immunol 1999; 163:427-433.

51. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3:221-227.

52. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009; 1:a000034.